Savaria (TSE:SIS) Price Target Raised to C$31.00

Savaria (TSE:SIS) had its target price increased by TD Securities from C$27.00 to C$31.00 in a research note published on Thursday,BayStreet.CA reports. TD Securities currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on SIS. Scotiabank raised their target price on Savaria from C$25.00 to C$26.00 in a research note on Monday, November 10th. Stifel Nicolaus boosted their target price on shares of Savaria from C$26.00 to C$28.00 and gave the company a “buy” rating in a research note on Wednesday, January 14th. Finally, National Bank Financial upped their target price on shares of Savaria from C$26.00 to C$30.00 in a research report on Monday, December 22nd. Seven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of C$30.93.

Savaria Stock Down 3.4%

Shares of TSE:SIS opened at C$25.52 on Thursday. The company’s fifty day moving average is C$24.64 and its two-hundred day moving average is C$22.53. The company has a debt-to-equity ratio of 8.27, a quick ratio of 0.91 and a current ratio of 1.61. Savaria has a 1-year low of C$14.97 and a 1-year high of C$26.42. The stock has a market capitalization of C$1.83 billion, a price-to-earnings ratio of 29.33, a price-to-earnings-growth ratio of 42.72 and a beta of 1.14.

Savaria (TSE:SIS) last posted its earnings results on Wednesday, March 4th. The company reported C$0.37 EPS for the quarter. The company had revenue of C$241.78 million during the quarter. Savaria had a return on equity of 11.10% and a net margin of 7.53%. Equities analysts anticipate that Savaria will post 1.2048518 EPS for the current year.

Key Stories Impacting Savaria

Here are the key news stories impacting Savaria this week:

• Positive Sentiment: Multiple brokerages raised price targets and upgraded ratings this morning (ATB Cormark to C$32, Raymond James to C$32, National Bank to C$30.50, Scotiabank to C$30, Desjardins to C$32, Stifel and TD also higher). These raises signal stronger analyst confidence and imply double‑digit upside from current levels. Analyst Rating Roundup
• Positive Sentiment: Savaria reported record 2025 results and stronger margins, with Q4 revenue of C$241.8M and EPS C$0.37 — results the company says position it for a new growth phase around its Savaria One strategy. This fundamental momentum underpins the analyst upgrades. Record 2025 Results
• Positive Sentiment: Coverage pieces note Savaria “entering a new growth phase” after completion of Savaria One and record Q4, reinforcing the narrative for higher future growth and margin improvement. Growth Phase Article
• Neutral Sentiment: The shares briefly hit a 12‑month high following the analyst activity and results, attracting attention from retail and institutional traders. 12‑Month High Coverage
• Neutral Sentiment: Management’s earnings release and conference call are available for review (detailed Q4 release and call transcript), useful for investors who want to assess guidance and cadence of margin improvement. Press Release / Transcript
• Negative Sentiment: Despite the positive newsflow, the stock is lower — likely reflecting short‑term profit‑taking after a run to a 52‑week high, elevated trading volume, and valuation concerns (current reported P/E ~29 and very high PEG). Those factors can pressure the share price even amid upgrades. Market Data / Valuation

About Savaria

Savaria Corporation ( savaria.com ) is a global leader in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and elevators for home and commercial use. It also manufactures and markets a comprehensive selection of pressure management products for the medical market, medical beds for the long-term care market, as well as an extensive line of medical equipment and solutions for the safe handling of patients, including ceiling lifts and slings.